(Reuters) – The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström’s macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists.
Steven Treon, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, outlines the current outlook of Waldenstrms macroglobulinemia (WM), from hand-me-down to targeted approaches. The discovery …
CONCLUSIONS: We showed that comparative microarray profiles allowed to gain more comprehensive insights into the biology of WM. The data presented here have implications for the development of novel therapies, such as targeting aberrant T-cell markers in WM.
PMID: 30279229 [PubMed – as supplied by publisher]
CONCLUSIONS: These results support the clinical investigation of KPT-9274 in combination with DNA-damaging agent for treatment of WM.
PMID: 30206161 [PubMed – as supplied by publisher]
CONCLUSION: Taken together, these data support the translation of R191 as an approach to target IRAK1/4 to the clinic for Waldenström’s macroglobulinemia patients.
PMID: 30126942 [PubMed – as supplied by publisher]
Publication date: Available online 31 March 2017Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Patrick Eulitt, Denise Fabian, Crystal Kelly, Jessica Hemminger, Basem M. WilliamAbstractWaldenström’s macroglobulinemia is a rare hematology malignancy which often presents with “B symptoms,” anemia, and thrombocytopenia. A 46-year-old woman presented with 2 months of abdominal distension accompanied by an unintentional 20-lb weight loss. Her abdominal CT scan demonstrated diffuse carcinomatosis with bilateral ovarian lesions and screening labs revealed a markedly elevated CA-125, suggesting a…
The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström’s macroglobulinemia (WM) treatment, including patients with prior lines of therapy and variou… Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, Waldenström’s Macroglobulinemia
Conclusion: Increased diffuse BM 18F-FDG uptake can be attributed to both bone marrow MI and benign etiologies. A decision tree based on C5.0 algorithm, combining PET/CT imaging and clinical features, is of potential use in discriminating BM malignant infiltration from patients with increased diffuse BM uptake.
We report two patients, one with multiple myeloma and one with Waldenstrom’s macroglobulinemia, who developed cutaneous necrot izing vasculitis after the initiation of ixazomib. Both patients exhibited no signs of systemic vasculitis and completed their anti-cancer regimens with resolution of their respective eruptions following dose reductions in ixazomib and initiation of low-dose prednisone. A collaborative effort toward s the characterization of such cutaneous toxicities facilitates early intervention, maintenance of life-preserving anti-cancer therapy, and allows clinicians opportunity to better understand the p…
Waldenström macroglobulinemia treatment algorithm 2018Waldenström macroglobulinemia treatment algorithm 2018, Published online: 01 May 2018; doi:10.1038/s41408-018-0076-5Waldenström macroglobulinemia treatment algorithm 2018